Last reviewed · How we verify
Luveris increasing dose
Luveris is a recombinant human luteinizing hormone (LH) that stimulates ovarian steroidogenesis and follicle development in women undergoing assisted reproductive technology.
Luveris is a recombinant human luteinizing hormone (LH) that stimulates ovarian steroidogenesis and follicle development in women undergoing assisted reproductive technology. Used for Infertility in women undergoing assisted reproductive technology (ART) requiring ovarian stimulation.
At a glance
| Generic name | Luveris increasing dose |
|---|---|
| Sponsor | University Reproductive Associates |
| Drug class | Gonadotropin |
| Target | LH receptor (LHCGR) |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
Luveris binds to LH receptors on theca cells in the ovary, promoting androgen production which is then converted to estrogen by granulosa cells. This hormone is used in combination with follicle-stimulating hormone (FSH) to support controlled ovarian hyperstimulation during fertility treatment. The increasing dose regimen allows titration to optimize follicle development while minimizing ovarian hyperstimulation syndrome risk.
Approved indications
- Infertility in women undergoing assisted reproductive technology (ART) requiring ovarian stimulation
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Headache
- Injection site reactions
- Abdominal pain/discomfort
- Nausea
Key clinical trials
- Rec-LH PD and Safety Profile in Hypogonadotropic Hypogonadism Men (PHASE2)
- The Luveris In Vitro Fertilization Trial (PHASE4)
- The Evaluation of Recombinant LH Supplementation in Patients With Suboptimal Response to Recombinant FSH Undergoing ICSI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Luveris increasing dose CI brief — competitive landscape report
- Luveris increasing dose updates RSS · CI watch RSS
- University Reproductive Associates portfolio CI